The United States Thrombotic Microangiopathy Alliance and Consortium Announces Website Launch
Groveport, OH (PRUnderground) August 3rd, 2022
Offering patients necessary resources, the United States Thrombotic Microangiopathy Alliance and Consortium (USTMA) has launched a new website. The site will increase the understanding of patients facing this rare disease with a knowledge base from the foremost leading experts in Thrombotic Microangiopathy (TMA). Among other services, the new site allows patients to speak with experts, study an extensive listing of treatment guidelines, and read about new research.
A USTMA representative said, “Our organization started as a group of physicians banding together to do research. Then, it quickly grew into a patient advocacy component. Now, the consortium is the organization’s research arm, and the alliance is all patient advocacy.”
With advocacy at the fore, USTMA has expanded the focus of the National Patient Meeting to include other patient groups. Most recently, the organization has increased its reach from Thrombotic Thrombocytopenic Purpura (TTP) to include all TMA and Atypical Hemolytic Uremic Syndrome (aHUS). This expansion consists of a biobank and registry for all TMA interests. The biobank will foster ongoing future research that will result in better outcomes for patients.
USTMA is slated to host its national meeting for the third year running.
For more information, visit https://www.USTMA.org.
Director of Operations
United States Thrombotic Microangiopathy Alliance and Consortium offers education and advocacy for patients diagnosed with TMA. They create educational videos and treatment guidelines and host an annual meeting.